• SynAm Vaccine
  • Rockville Innovation Center
  • 155 Gibbs Street, #552
  • Rockville, Maryland 20850
twitter logo

for investment and partnering inquiries:

twitter logo

SynAm Vaccine's mission is to eradicate pneumococcal diseases — pneumonia, middle ear infections, and meningitis — with the world's first universal vaccine. Pneumococcal diseases are the leading cause of serious illness in children and adults throughout the world and account for more deaths than all other vaccine-preventable bacterial diseases combined.

SynAm Vaccine's lead universal vaccine candidate addresses the critical unmet medical need in the marketplace by providing universal coverage against all 91 bacteria serotypes, while current marketed vaccines cover only a fraction of the serotypes.

management team

  • Don Chen, Ph.D.
  • Co-Founder
  • Chairman of the Board, President, Chief Executive Officer
  • Ming-chi Wu, Ph.D.
  • Co-Founder
  • Director, Chief Scientific Advisor
  • Michael Chen, Ph.D.
  • Vice President
  • Patent and Preclinical Research & Development
  • Carolyn Chen, MBA
  • Vice President
  • Business Development

scientific advisors

  • David Ho, M.D.
  • Medical Advisor, Time Magazine Man of the Year
  • Chief Executive Officer, Aaron Diamond AIDS Research Center
  • The Rockefeller University
  • Yuan Tseh Lee, Ph.D.
  • Scientific Advisor, Nobel Laureate in Chemistry
  • President, International Council for Science
  • Mathuram Santosham, M.D., M.P.H.
  • Medical Advisor
  • Professor, Departments of International Health and Pediatrics
  • Bloomberg School of Public Health, Johns Hopkins University